Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech AS's ROE % for the quarter that ended in Mar. 2026 was -121.71%. Cessatech AS's PB Ratio for the quarter that ended in Mar. 2026 was 34.84.
Cessatech AS's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -3.49%.
Cessatech AS ROE % Adjusted to Book Value Related Terms
Cessatech AS ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Cessatech AS's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSAT:CESSA vs VRTX, REGN, RVMD: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Cessatech AS's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Cessatech AS's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -3.49% mean?
Cessatech AS (XSAT:CESSA) has a ROE % Adjusted to Book Value of -3.49% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cessatech AS and its competitors.
Is Cessatech AS's ROE % Adjusted to Book Value too high?
Cessatech AS's current ROE % Adjusted to Book Value is -3.49%. Overall, Cessatech AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's ROE % Adjusted to Book Value compare to VRTX and REGN?
Cessatech AS's ROE % Adjusted to Book Value of -3.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cessatech AS and its competitors. Cessatech AS's current ROE % Adjusted to Book Value is -3.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (XSAT:CESSA) has a current ROE % Adjusted to Book Value of -3.49%. The current ROE % Adjusted to Book Value is -3.49%. Cessatech AS's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cessatech AS (XSAT:CESSA), the current ROE % Adjusted to Book Value is -3.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score
Get the complete analysis for XSAT:CESSA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:CESSA has been successfully added to your 
